Blocking muscle wasting via deletion of the muscle-specific E3 ubiquitin ligase MuRF1 impedes pancreatic tumor growth.
Daria NeyroudOrlando LaitanoAneesha DasguptaChristopher LopezRebecca SchmittJessica SchneiderDavid HammersLee SweeneyGlenn WalterJason DolesSarah JudgeAndrew R JudgePublished in: Research square (2023)
Cancer-induced muscle wasting reduces quality of life, complicates or precludes cancer treatments, and predicts early mortality. Herein, we investigated the requirement of the muscle-specific E3 ubiquitin ligase, MuRF1, for muscle wasting induced by pancreatic cancer. Murine pancreatic cancer (KPC) cells, or saline, were injected into the pancreas of WT and MuRF1-/- mice, and tissues analyzed throughout tumor progression. KPC tumors induced progressive wasting of skeletal muscle and systemic metabolic reprogramming in WT mice, but not MuRF1-/- mice. KPC tumors from MuRF1-/- mice also grew slower, and showed an accumulation of metabolites normally depleted by rapidly growing tumors. Mechanistically, MuRF1 was necessary for the KPC-induced increases in cytoskeletal and muscle contractile protein ubiquitination, and the depression of proteins that support protein synthesis. Together, these data demonstrate that MuRF1 is required for KPC-induced skeletal muscle wasting, whose deletion reprograms the systemic and tumor metabolome and delays tumor growth.
Keyphrases
- skeletal muscle
- klebsiella pneumoniae
- high glucose
- insulin resistance
- diabetic rats
- high fat diet induced
- drug induced
- gene expression
- multiple sclerosis
- endothelial cells
- type diabetes
- cardiovascular disease
- oxidative stress
- induced apoptosis
- cardiovascular events
- cell death
- mass spectrometry
- deep learning
- binding protein
- small molecule
- wild type
- data analysis